title: Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-α2 chain-null congenital muscular dystrophy mice.
abstract: Phosphorodiamidate morpholino oligomer (PMO)-mediated exon skipping is among the more promising approaches to the treatment of several neuromuscular disorders including Duchenne muscular dystrophy. The main weakness of this approach arises from the low efficiency and sporadic nature of the delivery of charge-neutral PMO into muscle fibers, the mechanism of which is unknown. In this study, to test our hypothesis that muscle fibers take up PMO more efficiently during myotube formation, we induced synchronous muscle regeneration by injection of cardiotoxin into the tibialis anterior muscle of Dmd exon 52-deficient mdx52 and wild-type mice. Interestingly, by in situ hybridization, we detected PMO mainly in embryonic myosin heavy chain-positive regenerating fibers. In addition, we showed that PMO or 2'-O-methyl phosphorothioate is taken up efficiently into C2C12 myotubes when transfected 24-72 h after the induction of differentiation but is poorly taken up into undifferentiated C2C12 myoblasts suggesting efficient uptake of PMO in the early stages of C2C12 myotube formation. Next, we tested the therapeutic potential of PMO for laminin-α2 chain-null dy(3K)/dy(3K) mice: a model of merosin-deficient congenital muscular dystrophy (MDC1A) with active muscle regeneration. We confirmed the recovery of laminin-α2 chain and slightly prolonged life span following skipping of the mutated exon 4 in dy(3K)/dy(3K) mice. These findings support the idea that PMO entry into fibers is dependent on a developmental stage in myogenesis rather than on dystrophinless muscle membranes and provide a platform for developing PMO-mediated therapies for a variety of muscular disorders, such as MDC1A, that involve active muscle regeneration.
authors.affiliation: Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP), Ogawa-Higashi 4-1-1, Kodaira, Tokyo 187-8502, Japan.
authors.forename: Yoshitsugu
authors.initials: Y
authors.lastname: Aoki
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Nagata
authors.forename: Toshifumi
authors.initials: T
authors.lastname: Yokota
authors.forename: Akinori
authors.initials: A
authors.lastname: Nakamura
authors.forename: Matthew J A
authors.initials: MJ
authors.lastname: Wood
authors.forename: Terence
authors.initials: T
authors.lastname: Partridge
authors.forename: Shin'ichi
authors.initials: S
authors.lastname: Takeda
mesh_terms: D017398:Alternative Splicing; D000818:Animals; D001483:Base Sequence; D001973:Bromodeoxyuridine / Q000378:metabolism; D054715:Cardiotoxins / Q000008:administration & dosage; D002460:Cell Line; D002463:Cell Membrane Permeability / Q000235:genetics; D004195:Disease Models, Animal; D016189:Dystrophin / Q000737:chemistry / Q000172:deficiency / Q000235:genetics / Q000378:metabolism; D005091:Exons; D015870:Gene Expression; D023061:Gene Order; D006801:Humans; D007797:Laminin / Q000235:genetics* / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D060172:Morpholinos / Q000008:administration & dosage / Q000737:chemistry / Q000378:metabolism*; D018485:Muscle Fibers, Skeletal / Q000145:classification / Q000187:drug effects / Q000378:metabolism*; D009136:Muscular Dystrophies / Q000235:genetics* / Q000378:metabolism* / Q000401:mortality; D009137:Muscular Dystrophy, Animal; D020388:Muscular Dystrophy, Duchenne / Q000235:genetics / Q000378:metabolism; D012038:Regeneration
chemical_list: D054715:Cardiotoxins; D016189:Dystrophin; D007797:Laminin; D060172:Morpholinos; C102645:laminin alpha 2; D001973:Bromodeoxyuridine